Katelyn Ward
About Katelyn Ward
Katelyn Ward is an Automation Engineer specializing in Cell Therapy at Bristol Myers Squibb in Seattle, Washington, with a background in both academic and commercial research environments.
Title
Katelyn Ward is currently an Automation Engineer specializing in Cell Therapy. She is based in Seattle, Washington, and works for Bristol Myers Squibb.
Company
Katelyn Ward is employed by Bristol Myers Squibb, a global biopharmaceutical company. She contributes to the development of cell therapy solutions within the company.
Work Experience at Ascent Services Group
Katelyn worked at Ascent Services Group as a Research Associate from 2019 to 2021. During her two-year tenure, she focused on various research initiatives in Seattle, Washington, expanding her expertise in the field.
Work Experience at Allen Institute for Brain Science
Katelyn Ward served as a Research Associate I from 2016 to 2018 and was later promoted to Research Associate II from 2018 to 2019 at the Allen Institute for Brain Science. Based in South Lake Union, Seattle, she contributed to brain science research, advancing from entry-level roles to higher responsibilities.
Education and Background
Katelyn Ward holds a Bachelor of Science in Biology/Biological Sciences from Washington State University, where she studied from 2009 to 2014. Her academic background provided a solid foundation in both theoretical and practical aspects of biological sciences.
Early Professional Experience
Katelyn’s early professional journey began at Pathologists' Regional Laboratory where she worked as a Medical Laboratory Technician from 2014 to 2015 in Lewiston, Idaho. She gained hands-on experience in a clinical laboratory setting, which laid the groundwork for her future roles in research.
Transition from Plant Physiology to Brain Science and Cell Therapy
Katelyn transitioned from plant physiology research, where she worked as an Undergraduate Research Assistant at Washington State University's Hellmann Lab in 2014, to brain science and eventually cell therapy. This shift showcases her adaptability and eagerness to broaden her scientific expertise.